D'Angelo, S., Tirri, E., Giardino, A.M., Derosa, T., Matucci-Cerinic, M., Dagna, L., et al. (2024). Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 27(3) [10.1111/1756-185X.15091].
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study
Frediani B.;
2024-01-01
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Int J of Rheum Dis - 2024 - D_Angelo - Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNF drug.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
871.15 kB
Formato
Adobe PDF
|
871.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/1267655